Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status Prescription
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 60505-3250; 53873-075; 53873-073; 55773-0589; 49702-204; 49702-203; 50742-623; 65015-701; 68180-603; 50742-624; 65862-259; 53873-074; 54838-566; 31722-752; 64380-711; 49702-205; 31722-001; 70159-001; 52482-003; 64380-710; 31722-753; 68554-0043; 65862-026; 33342-001; 69097-167; 70518-3267; 57237-274; 65015-756; 70518-2067; 70518-2070; 67835-0017; 0173-0662; 53104-7538; 60687-362; 0173-0663; 60505-3252; 53104-7677; 65862-025; 68180-602; 65862-055; 68554-0016; 66993-478; 31722-754; 65862-577; 69097-166; 42385-714; 33342-002; 60505-3251; 60429-354; 60429-353; 0904-6583
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neonatal respiratory failure18.04.17.003; 22.11.02.0110.009276%Not Available
Pulmonary valve stenosis02.07.04.0050.004638%Not Available
Pulmonary valve stenosis congenital03.07.05.016; 02.07.04.0060.009276%Not Available
Renal failure neonatal20.01.03.024; 18.04.01.0190.009276%Not Available
Small for dates baby18.04.02.0020.018551%Not Available
Ventricular hypoplasia03.07.11.003; 02.08.01.0110.009276%Not Available
Blood HIV RNA increased13.08.03.0030.176239%Not Available
Mitochondrial cytopathy14.11.02.0080.009276%Not Available
Mitochondrial DNA deletion14.11.02.006; 03.18.01.0040.009276%Not Available
Foetal cardiac disorder18.03.02.013; 02.01.01.0160.001210%Not Available
Mitochondrial DNA mutation14.11.02.007; 03.18.01.0050.001210%Not Available
Intrauterine infection18.03.03.007; 11.01.10.0180.001815%Not Available
Carnitine deficiency14.08.04.0220.016233%Not Available
Hepatitis B DNA assay positive13.08.03.0180.006957%Not Available
Escherichia infection11.02.10.0040.004638%Not Available
Viral load increased13.08.03.0350.018551%Not Available
Viral mutation identified13.08.03.0360.208704%Not Available
Bicuspid pulmonary valve03.07.05.004; 02.07.04.0020.009276%Not Available
Atrioventricular septal defect03.07.02.005; 02.04.02.0290.009276%Not Available
Persistent left superior vena cava24.03.03.038; 03.07.04.0030.009276%Not Available
Acute hepatitis C11.05.06.007; 09.01.09.0110.006957%Not Available
Virologic failure11.01.08.062; 08.06.01.0340.322332%Not Available
Hepatitis B DNA increased13.08.03.0190.027827%Not Available
Distributive shock24.06.02.0220.004638%Not Available
Infantile apnoea22.11.02.004; 18.04.15.0030.009276%Not Available
End stage renal disease20.01.03.0190.004638%Not Available
The 13th Page    First    Pre   13    Total 13 Pages